In addition, the EMRGPI was positively associated with the 54 immune checkpoints (Figure 2E), among which CD80 (HR: 1.76, 95%CI: 1.03-3.00, p=0.037; Figure 2F), ADORA2A (HR: 2.02, 95%CI: 1.09-3.44, p=0.01; Figure 2G), CD160 (HR: 2.29, 95%CI: 1.32-3.96, p=0.003; Figure 2H), and TNFRSF25 (HR: 1.92, 95%CI: 1.13-3.26, p=0.016; Figure 2I) were significantly related to the BCR-free survival of PCa patients undergoing RP. Here, ADORA2A is linked to posterior cortical atrophy.